Emyria (ASX:EMD) has reached an agreement with Matilda Healthcare to open an Empax clinic at Matilda Nepean Private Hospital in Kingswood, expanding the company's presence in New South Wales and increasing its national footprint.
The clinic will be a dedicated four-room facility with four new treatment beds in Sydney and is targeted to commence in the third quarter of 2026, subject to regulatory approvals.
The Kingswood site was chosen for its strategic reach into Western Sydney and the broader North West New South Wales region, including Dubbo, Orange, Bathurst, Tamworth and Mudgee, and will complement existing specialist trauma and mood disorder services.
The new site expands the Empax network to five locations across four jurisdictions and raises treatment bed capacity to 18. Existing operating sites include two centres in Perth, an Avive clinic in Brisbane and the Mornington Peninsula clinic.
The company says the network will accelerate real-world data collection and underpin its Empax Global Partnership Program, which broadens geographic reach for international drug sponsors and clinical trial partners. See the summary of national sites on page 2.
Emyria is actively recruiting clinical staff in New South Wales and preparing workforce training. Authorised Prescriber approvals have doubled from 6 to 12, with 6 new approvals recently granted to support Perth, Brisbane and Mornington Peninsula clinics. A further eight psychiatrists are expected to attend New South Wales Empax training in June, and seven psychiatrists are due to attend New South Wales training to support expansion.
Executive Chair Greg Hutchinson said, “Establishing an Empax clinic in New South Wales provides Emyria a presence in every major Australian State and Territory, and increases treatment room capacity to 18. Matilda Healthcare was selected for its strategic reach into Western Sydney and the underserved North West New South Wales region. Combined with the launch of the Empax Global Partnership Program and recent Authorised Prescriber approvals, this further expansion provides Emyria the national scale and clinical workforce to help deliver on our ambition to be the leading platform for advanced mental health therapies in Australia, and as a global partner for international drug development sponsors.”
The binding terms include an initial three-year term with two further renewal options subject to utilisation conditions, a monthly licence fee with increased rates in year two, exclusive rights for psychedelic-assisted therapy at the facility and first right of refusal for other Matilda sites.